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Dear Sir,
The effect that oestrogen therapy exerts on markers of coagu-
lation and fibrinolysis in postmenopausal women depends on the
route of administration (oral or transdermal) (1–3) and whether
or not a progestogen is added (1–5). Recently, Scarabin et al.
found that transdermal oestrogen therapy, in contrast to oral ther-
apy, is not associated with an elevated risk of venous throm-
boembolism (6). This indicates that different forms of hormone
therapy not only differentially affect the balance of markers of
coagulation and fibrinolysis but also have different effects on the
risk of venous thromboembolism. In addition, the early in-
creased risk of coronary heart disease observed in postmenopau-
sal women using oral hormone therapy (7, 8) has been thought to
be related to procoagulatory changes.
Procarboxypeptidase U (proCPU, EC 3.4.17.20), also known
as thrombin-activatable fibrinolysis inhibitor (TAFI), is con-
sidered to be a link between coagulation and fibrinolysis (9–11).
During coagulation and fibrinolysis the active enzyme, carboxy-
peptidase U (CPU) is generated from proCPU (12). CPU exerts
its antifibrinolytic effect by removing C-terminal lysine residues
from partially degraded fibrin (11), thereby abrogating the en-
hanced plasminogen activation and preventing an acceleration of
fibrinolysis. Elevated levels of proCPU have been found to be a
mild risk factor for venous thrombosis (13) and were observed in
patients with angina pectoris (14).
Data on the effect of oral hormone therapy on proCPU levels
are scarce and inconclusive, whereas no data are available on the
effect of transdermal treatment. In the present study, we intend-
ed to elucidate the role of the route of oestrogen administration
and the effect of the addition of the progestogen gestodene to oral
oestradiol on proCPU levels.
The design of this study was published previously (2, 3,
15–18). Briefly, in this randomised, placebo-controlled, double-
blind, double-dummy, multicentre study, 152 healthy hysterec-
tomised postmenopausal women aged 45 to 65 years received
daily either placebo (n=49), or transdermal 17β-oestradiol (E
2
)
50 μg (Climara

, tE
2
group, n=33), or oral E
2
1 mg (oE
2
group,
n=37), or oral E
2
1 mg combined with gestodene 25 μg (oE
2
+G
group, n=33) for thirteen 28-day treatment cycles, followed by
four cycles of placebo for each group. The investigation con-
formed to the principles outlined in the Declaration of Helsinki.
Institutional Review Boards of all participating centres approved
the protocol. Written informed consent was obtained from each
participant before entry into the study.
Venous plasma samples were collected at baseline and in
cycles 4, 13 and 17 and stored at –80°C until analysis. Samples of
146 participants were available for analysis. Plasma proCPU
concentrations were determined by converting the zymogen to
its active form and subsequently measuring the carboxypepti-
dase activity with a colorimetric assay (5, 19, 20). The mean
intra-assay coefficient of variation was 3.7%.
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences PC + 9.0 (SPSS Inc., Chicago, Illi-
nois). ProCPU concentrations are given as mean ± standard devi-
ation (SD) and the individual percentage changes from baseline
as mean with 95% confidence interval (CI). Standard parametric
tests were performed. Analyses of covariance (ANCOVA) for re-
peated measurements, with the baseline concentrations of pro-
CPU and serum oestradiol as constant covariates, were used for
comparisons among and between the groups.
At baseline, no significant differences were found between
the groups in either proCPU levels or demographic character-
istics (age, body mass index (BMI), blood pressures, number of
smokers, serum cholesterol, FSH and oestradiol levels). The
women had an age of 54.6 ± 4.5 years (mean ± SD) and a BMI of
25.6 ± 2.9 kg/m
2
(mean ± SD).
In cycle 13, proCPU was significantly decreased in the tE
2
and oE
2
+G group compared to placebo (P<0.001), but not in the
oE
2
group (Table). The mean percentage changes from baseline
versus placebo were –8.6% [95% CI –12.1 to –5.1%] in the tE
2
group and –7.9% [95% CI –10.9 to –5.0%] in the oE
2
+G group.
The decreases were already apparent in cycle 4. Changes in the
tE
2
and oE
2
+G group differed significantly from the changes in
the oE
2
group. After four cycles of wash-out, when compared to
baseline and placebo, the decrease observed in the oE
2
+G group
persisted (–4.6% [95% CI –7.9 to –1.3%]).
In earlier randomised controlled trials and in the present
study it was observed that neither unopposed oral 17β-oestradiol
in a dosage of 1 or 2 mg daily (5) nor oral oestrogens combined
with dydrogesterone (5), medroxyprogesterone acetate (20), or
norethisterone acetate (21) changed proCPU levels. In contrast,
decreased plasma proCPU levels were observed during trans-
dermally administered oestradiol 50 μg daily and during oral
oestradiol combined with the progestogens gestodene or tri-
megestone (5). Taken together, data from randomised controlled
trials indicate that both the route of administration and the addi-
tion of different progestogens play a role in the effect of oes-
trogens on plasma proCPU. Consequently, this will have differ-
ential effects on the haemostatic balance and, therefore, may dif-
ferentially affect clinical venous and arterial thromboembolic
risk. However, results from the present study are puzzling, since
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Table: Plasma procarboxypeptidase U concentrations.
previous studies clearly showed that orally but not transdermally
administered oestrogens increase fibrinolysis.
Since the proenzyme proCPU is mainly produced in the liver,
the observed difference in effect of orally and transdermally ad-
ministered unopposed oestrogen may be the consequence of
avoiding the hepatic first-pass effects in the latter. Besides a de-
creased production, the observed reductions in plasma proCPU
levels can be the result of an increase in the conversion of pro-
CPU to active CPU as well.The activation of proCPU to CPU oc-
curs during coagulation and fibrinolysis by plasmin, thrombin,
and by a complex of thrombin with thrombomodulin (22).There-
fore, effects of transdermal oestradiol and oral oestradiol com-
bined with gestodene on these haemostatic factors may have
contributed to our observations.
In contrast to oral postmenopausal hormone therapy, trans-
dermally administered hormone therapy is not associated with
an increased risk of venous thrombosis (6). The risk of venous
thrombosis depends, in part, on the balance between markers of
coagulation and fibrinolysis. Since plasma proCPU plays a role
in this balance as well, differences in effect of the two routes of
administration on proCPU levels as observed in our study may
therefore contribute to the difference in venous thrombosis risk
in users of oral and transdermal hormone therapy.
In elderly women, oral combined oestrogen plus progestogen
therapy is possibly associated with a slightly early increased risk
for coronary heart disease (CHD) (7, 8), whereas a non-signifi-
cant increased risk of CHD was observed in elderly women using
a high dose of transdermal oestradiol (23). Interestingly, recent
data suggest a protective effect of oral unopposed oestrogen ther-
apy in postmenopausal women aged 50–59 years (24). Contra-
dictory results have been found in trials investigating the associ-
ation of proCPU levels and arterial thrombotic events (14, 25).
This might be the consequence of differences in study popu-
lations and the use of different assays (25). We want to stress that
the reductions in proCPU in relatively young postmenopausal
women as observed in our study should not be extrapolated to
elderly women who are at increased CHD risk during oral com-
bined oestrogen plus progestogen therapy.
In conclusion, transdermal unopposed oestradiol reduced
plasma proCPU levels whereas oral unopposed oestradiol did
not. Oral oestradiol combined with gestodene also lowered
proCPU levels. A reduction in proCPU may contribute to in-
creased fibrinolysis.
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Dear Sir
We read with interest the paper by Ignjatovic and colleagues (1)
and were encouraged to learn about their efforts to improve the
quality of their service to children and young people.
We were disturbed, however, at the way in which the study
was carried out and concerned about its conclusions. In particu-
lar, the idea that the laboratory venous method of INR deter-
mination should be deemed the “gold standard” is an extraordi-
nary assertion. The laboratory method described was an ACL
100 with Instrumentation Laboratory’s ILTest PT Fibrinogen.
The laboratory relied on the International Sensitivity Index (ISI)
assigned to the reagent by the manufacturer. No attempt was
made to determine a local system ISI.The authors used as justifi-
cation a paper by Hobbs et al. (2) describing a study to compare
INR measurements in hospital laboratories and primary care set-
tings. Hobbs et al. used three hospitals and applied the term
“gold standard” to the one which had taken the trouble to assign
a system ISI to their combination of coagulometer and thrombo-
plastin reagent. We do not believe that these authors were sug-
gesting that any laboratory INR method can be a “gold stan-
dard”!
We feel that the only proper way to undertake studies of this
sort must be to use manual prothrombin time testing with an In-
ternational Reference Preparation (IRP) as the “gold standard”,
or, at least, to perform a system ISI calibration of the laboratory
method to align it to the WHO system. Shiach et al. (3) described
the ideal approach in a comparison study by performing system
ISI for both laboratory and point of care testing. This should
surely be the model for similar studies.
Steven Craig, David Leeming, Allan Sidebotham , Ken Stevenson
Anticoagulation and Haematology Research Unit, South
Manchester University Hospitals Trust,Wythenshawe Hospital,
Manchester, UK
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